Literature DB >> 23370401

[Etiology and pathophysiology of benign prostate hyperplasia].

A Roosen1, C Gratzke, A Herrlemann, G Magistro, F Strittmatter, P Weinhold, S Tritschler, C G Stief.   

Abstract

The pathogenesis of benign prostate hyperplasia (BPH) is still unclear. It is a common disease affecting exclusively humans in its full clinical appearance. There is a broad variety of possible underlying mechanisms which most likely interact in the pathogenesis of the disease: inflammatory processes taking place predominantly in the stroma and inducing proliferation of all tissues within the transitional zone, an imbalance of androgens and estrogens and their receptors, hyperinsulinemia and hypercholesterolemia (metabolic syndrome) as direct promoters of glandular growth and autosomal dominant inheritance. The detrusor muscle responds to the increased outflow resistance with muscular hypertrophy. Decreased compliance of the bladder wall results in voiding difficulties while electric instability of the hypertrophied detrusor muscle and increased recruiting of otherwise silent afferent fibres cause storage symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370401     DOI: 10.1007/s00120-012-3083-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  30 in total

1.  Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

Authors:  Michael Marberger; Claus G Roehrborn; Leonard S Marks; Timothy Wilson; Roger S Rittmaster
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

Review 2.  The dual, opposing roles of estrogen in the prostate.

Authors:  Stuart J Ellem; Gail P Risbridger
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

Review 3.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

4.  Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy.

Authors:  J A Gosling; J S Dixon
Journal:  Urol Int       Date:  1980       Impact factor: 2.089

Review 5.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 6.  Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia.

Authors:  Zongwei Wang; Aria F Olumi
Journal:  Differentiation       Date:  2011-05-04       Impact factor: 3.880

7.  Clinical and biological characteristics of familial benign prostatic hyperplasia.

Authors:  M G Sanda; C B Doehring; B Binkowitz; T H Beaty; A W Partin; E Hale; E Stoner; P C Walsh
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  Serum sex hormones and measures of benign prostatic hyperplasia.

Authors:  Rosebud O Roberts; Debra J Jacobson; Thomas Rhodes; George G Klee; Michael M Leiber; Steven J Jacobsen
Journal:  Prostate       Date:  2004-10-01       Impact factor: 4.104

Review 9.  Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.

Authors:  Harry R Davis; Enrico P Veltri
Journal:  J Atheroscler Thromb       Date:  2007-06       Impact factor: 4.928

10.  Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Authors:  M Jiang; S Fernandez; W G Jerome; Y He; X Yu; H Cai; B Boone; Y Yi; M A Magnuson; P Roy-Burman; R J Matusik; S B Shappell; S W Hayward
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.